Directives de soumission d'échantillons
See Structure and Marker Localization in the Same Research Context
Histology and immunostaining answer complementary questions. H&E reveals overall morphology and tissue organization: whether the model forms expected epithelial arrangements, luminal structures, layered regions, stromal areas, necrotic zones, or other study-relevant features. IHC localizes selected antigens in tissue sections through a chromogenic signal that can be reviewed alongside morphology. IF uses fluorescent labels to distinguish selected targets, examine co-localization, and, with an appropriate preparation and imaging strategy, preserve more spatial information in a section or intact three-dimensional sample.
The methods become most useful when they are connected to a defined decision. A project may ask whether a model retains a source-associated architecture, whether a lineage marker is present in the expected compartment, whether a treatment changes a predefined state marker, or whether different passages show consistent organization. We translate that question into a comparison plan before staining begins.
This page covers focused protein-marker evidence as part of organoid characterization. It does not turn immunostaining into an untargeted protein profiling service. If the main uncertainty is an unknown cell population, a broad expression program, or a spatially resolved molecular state, our organoid sequencing services may provide a more appropriate next step. For projects requiring several connected modules, the organoid research solution coordinates model work, characterization, sequencing, and interpretation.
Choose the Preparation Route Before Staining
The most important technical decision often happens before the first stain is applied. Fixation, matrix handling, embedding, orientation, section thickness, permeabilization, and mounting determine which structures remain visible and whether antibodies can reach their targets. A method that is well suited to routine morphology may not be the best route for a fragile antigen or a three-dimensional localization question.
Paraffin Sections
Formalin-fixed, paraffin-embedded preparation is useful when the project needs stable blocks, serial sections, familiar H&E morphology, and repeatable review across multiple markers. It is often a practical route for side-by-side comparison of organoids and compatible source or reference tissue. Orientation and embedding strategy matter because small organoids can be lost, folded, compressed, or sectioned away from the region of interest.
Best for: conventional H&E review, serial-section IHC, archived block-based studies, and projects that prioritize section morphology.
Not automatically best for: antigens that are sensitive to fixation or antigen retrieval, studies requiring intact three-dimensional context, or samples whose architecture is easily distorted during processing.
Cryosections
Frozen preparation can shorten the path from fixation to sectioning and may preserve selected antigens or fluorescent proteins better than paraffin processing. It can also be helpful when the research plan includes IF and morphology can be interpreted on cryosections. However, freezing and sectioning can introduce tears, folds, ice-crystal artifacts, or variable morphology, particularly in delicate organoids or poorly supported matrices.
Best for: selected antigen-preservation needs, section-based IF, and projects in which compatible fluorescent signals are important.
Not automatically best for: studies that require paraffin-quality morphology, long-term block handling, or serial sections with highly consistent architecture.
Whole-Mount Immunofluorescence
Whole-mount IF preserves the intact organoid and can reveal how selected markers are distributed through a three-dimensional structure. It may support z-stack acquisition, optical sectioning, and three-dimensional rendering when organoid size, optical properties, antibody penetration, clearing, and imaging capability are compatible. The same three-dimensional context also creates technical constraints: residual extracellular matrix, dense tissue, inadequate permeabilization, limited antibody penetration, and background signal can produce an apparent gradient that is methodological rather than biological.
Best for: intact spatial relationships, selected three-dimensional localization questions, and visualization that cannot be reconstructed reliably from a small number of sections.
Not automatically best for: large or optically dense samples without a validated penetration and clearing strategy, high-throughput routine review, or projects that need conventional H&E morphology on the same intact specimen.
Route selection is finalized after feasibility review. In some projects, matched aliquots are prepared through different routes so H&E architecture, section-based marker evidence, and whole-mount spatial information can be interpreted together. This does not mean every organoid must undergo every method. Each route is included only when it contributes evidence that changes the research decision.
Build a Marker Panel Around the Biological Question
A long marker list is not automatically a strong panel. Marker selection begins with the cell identity, differentiation state, structural compartment, proliferation state, stress response, or microenvironment component that the study needs to evaluate. We review the expected localization of each target, available antibody information, host species and fluorophore compatibility, tissue and organoid controls, and the preparation route before the panel is confirmed.
A practical panel often contains several roles rather than several versions of the same evidence:
- Identity markers test whether a selected lineage or cell type is represented.
- Differentiation or maturation markers address a defined developmental or functional state.
- Structural markers locate epithelial, stromal, basement-membrane, junctional, or polarity-associated features.
- State markers evaluate a predefined process such as proliferation, apoptosis, hypoxia, or stress within the limits of the selected targets.
- Microenvironment markers locate selected stromal or immune components in co-culture or assembloid research models.
- Reference stains or counterstains place the target signal within a recognizable tissue or nuclear context.
No universal marker panel can establish that every organoid is faithful to its source or suitable for every downstream application. Marker expression may vary with organoid type, passage, maturation, culture condition, treatment, and sample handling. A positive signal shows that the selected target was detected under the tested conditions; it does not provide an unbiased inventory of cell states. A negative signal may reflect biology, but it can also result from fixation, retrieval, penetration, antibody compatibility, or imaging settings. That is why the panel and controls are reviewed together.
Controls Are Part of the Assay Design
Controls are selected according to the claim the study needs to support. They may include a known positive material, an appropriate negative or omission control, an untreated or baseline organoid, a matched source or reference tissue, an independent culture batch, or a comparison across passage or condition. For multiplex IF, single-stain controls and channel review may be needed to distinguish biological co-localization from spectral overlap or image-processing artifacts.
The report records which controls were used and what they allow the reviewer to conclude. When a suitable control is not available, that limitation is identified before the project proceeds rather than hidden after imaging.
From Sample Review to a Traceable Image Set
Our workflow connects the laboratory steps with the final interpretation so that a reviewer can trace an image back to the model, condition, section, stain, and analysis rule.
- Research-question and comparison review. We define the feature to be evaluated, the biological unit, comparison groups, relevant passages or batches, and the decision that will follow from the result.
- Material and metadata assessment. We review organoid type, culture matrix, condition, preservation state, prior fixation, available controls, target markers, and any planned downstream assay.
- Preparation-route selection. Paraffin section, cryosection, whole-mount IF, or a project-defined combination is selected according to morphology, antigen, penetration, orientation, imaging depth, and material constraints.
- Pilot and condition optimization where needed. A limited pilot may evaluate recovery, fixation, retrieval, antibody dilution, blocking, permeabilization, exposure, or background before the full sample set is processed.
- Embedding, sectioning, or whole-mount preparation. Samples are handled with an orientation and recovery plan appropriate to small three-dimensional structures. Processing records connect each preparation with its source identifier.
- H&E, IHC, and/or IF staining. The confirmed panel and controls are processed using the agreed route. Multiplex designs are checked for antibody and channel compatibility before the final run.
- Imaging and quality review. Fields, regions, magnification, channels, and acquisition settings are selected according to the comparison. Focus, exposure, background, tissue integrity, and control behavior are reviewed before quantitative analysis.
- Project-defined image analysis. When requested and feasible, a documented rule set is applied to area, intensity, counts, co-localization, spatial distribution, or another predefined metric.
- Reporting and data handoff. The deliverable links representative findings, image files, annotations, analysis tables, methods, controls, and limitations to the original project design.
This workflow is modular. A straightforward H&E comparison does not need every optimization step, while a multiplex whole-mount IF study may require a pilot before the complete panel is processed. The project scope is designed to reduce avoidable sample consumption without promising that every target will work under a single universal condition.
Sample and Project Information Required
Exact quantities, containers, preservation conditions, and shipping instructions are confirmed after feasibility review because requirements depend on model size, culture format, preparation route, marker panel, and number of comparisons.
| Material or information | Why it matters | Questions reviewed before work begins |
|---|---|---|
| Cultured or fixed organoids | Defines the primary experimental material | Organoid type, source, matrix, size range, passage, batch, condition, viability or fixation state |
| Blocks, sections, or slides | May allow staining without repeating upstream processing | Fixative, embedding medium, section type, age, storage, orientation, slide coating, prior stains |
| Matched source or reference material | Supports a direct structural or marker comparison when scientifically appropriate | Matching identifiers, tissue composition, preservation compatibility, availability, intended comparison |
| Control organoids or baseline condition | Helps separate the study variable from culture and handling effects | Control type, concurrent processing, batch relationship, biological replication |
| Marker and antibody information | Determines panel feasibility and optimization needs | Target, expected localization, species reactivity, clone, host, conjugate, prior validation, multiplex compatibility |
| Existing images or pilot results | Reveals morphology, background, or localization issues before full processing | Acquisition method, magnification, channels, exposure, annotations, observed artifacts |
| Downstream sequencing plan | Prevents fixation or allocation choices from compromising later molecular work | Assay type, matched aliquots, collection time point, required metadata, preservation compatibility |
If organoids are still being established or expanded, our organoid model development services can coordinate culture milestones with the future histology collection point. This avoids selecting a passage or collection condition after the sample has already been consumed.
Image Quantification Is Defined Before It Is Calculated
Quantification can make a comparison more consistent, but only when the metric, biological unit, sampling rule, segmentation approach, and exclusion criteria are defined in advance. A percentage or intensity value is not self-interpreting. It depends on how the organoid boundary was identified, which regions were sampled, how background was handled, and whether multiple fields represent one organoid, one well, or independent biological material.
Depending on the project and image quality, outputs may include:
- positive area or signal fraction within a defined region;
- mean, median, or integrated signal intensity after a documented background rule;
- target-positive object or cell counts using project-defined segmentation;
- distance, compartment, or radial-distribution measurements;
- overlap or co-localization metrics for predefined channels;
- organoid-level summaries across passages, batches, or conditions;
- annotated review panels linking quantitative values to the underlying image.
We do not use a universal threshold across unrelated markers, tissues, or acquisition settings. Thresholds and segmentation rules are tested against representative images and controls, then held consistent within the agreed comparison where possible. If staining quality, section damage, autofluorescence, saturation, or uneven penetration makes a metric unreliable, the affected measurement is flagged rather than converted into a confident biological claim.
Conventional bioinformatics is not the core of this service. The analytical component is digital image analysis tied to the staining experiment. When the research question requires discovery-level cell-state analysis or transcriptome-wide interpretation, the project should move to sequencing rather than treating a larger stain panel as a substitute.
What You Receive
Deliverables are defined before processing and can be adjusted to the confirmed scope. A project may include:
- a sample and comparison map;
- preparation, staining, and imaging method records;
- H&E overview and selected higher-magnification images;
- IHC or IF image sets with channels or composite views as agreed;
- control review and assay-specific quality notes;
- annotated representative regions;
- project-defined quantitative tables and plots when included;
- a findings summary that separates observations from interpretation;
- limitations and recommendations for repeat staining, another preparation route, or downstream sequencing;
- agreed raw and processed image files.
The report does not reduce model quality to a universal pass/fail score. It states which predefined features were observed, which comparisons were supported, and which questions remain unresolved. This makes the result useful to the person who ordered the study, the scientist reviewing it, and the sequencing team that may receive matched material later.
When Histology Is Enough—and When Sequencing Adds Value
Histology and immunostaining are strong choices when the targets are predefined and location matters. They can show whether a marker sits in an expected compartment, whether selected structures are preserved, and whether a planned condition is associated with a visible change. They are not unbiased surveys of all cell types, pathways, or molecular states.
| Research question | Histology/immunostaining role | When another method is more appropriate |
|---|---|---|
| Does the organoid show the expected architecture? | H&E can document structure and selected morphological features | Add sequencing when molecular programs, not visible structure, drive the decision |
| Is a predefined lineage or state marker present and localized? | IHC or IF can test the selected target in tissue context | Use single-cell or single-nucleus RNA sequencing when cell populations are not known in advance |
| Do two selected markers occupy the same region? | Multiplex IF may support co-localization or spatial-distribution analysis | Use spatial transcriptomics when broader molecular programs must be mapped in context |
| Are source and organoid similar across all biological levels? | Histology contributes structural and targeted protein evidence | No single stain can establish global fidelity; combine with genetic or transcriptomic evidence as required |
| Did passage or treatment change a known feature? | A controlled stain panel can compare the predefined feature | Use a broader molecular assay when the mechanism or affected cell state is unknown |
The organoid characterization services page helps select evidence across morphology, markers, genetics, and sequencing readiness. This histology page handles the tissue preparation, H&E, IHC, IF, imaging, and reporting component as one package.
Illustrative Result Formats
The following planned visuals explain common deliverable structures. They are illustrative examples, not customer data and not performance claims.
H&E Architecture Comparison
A matched panel can place source or reference material beside organoid sections at overview and selected higher magnification. The accompanying annotation identifies the structural features reviewed, the orientation, and any processing artifact that limits comparison. Similar appearance is described only for the tested sections and features.
IHC Marker Localization
A chromogenic marker panel can combine a morphology-preserving counterstain with a project-defined antigen. Representative regions are linked to control behavior and, when included, a consistent positive-area or object-counting rule. The output shows where the selected target was detected; it does not imply a complete cell-type inventory.
IF Co-localization and Three-Dimensional Context
A multichannel IF panel can show nuclei and selected markers as individual channels and composites. Section-based IF supports compartment review, while whole-mount acquisition may add z-stacks or three-dimensional rendering when penetration and optical conditions are suitable. Co-localization is interpreted using the agreed image and analysis rules, not by visual overlap alone.
Organoid Histology and Immunostaining FAQs
Should I choose H&E, IHC, or IF for my organoid study?
Choose according to the question. H&E is suited to overall morphology and architecture. IHC localizes predefined targets in a section with a chromogenic signal. IF supports multichannel localization and, with the right preparation, three-dimensional imaging. A project may combine them when each method answers a distinct uncertainty.
Can the same organoid be used for H&E, IHC, IF, and sequencing?
Not usually as one physical specimen because fixation, embedding, whole-mount staining, nucleic-acid extraction, and sequencing require different preparation routes. Matched organoids or aliquots should be collected from aligned culture points and tracked under the same sample map.
Do you offer whole-mount immunofluorescence?
Whole-mount IF can be considered when the organoid, target, matrix, sample size, antibody penetration, optical clearing, and imaging plan are compatible. Feasibility is reviewed before it is promised, and a pilot may be recommended for a new model or antibody combination.
Can I submit my own antibodies?
Client-specified antibodies can be reviewed for target relevance, species reactivity, clone information, host species, conjugation, prior use, and multiplex compatibility. Acceptance and optimization scope depend on available evidence, controls, and sample material.
Can you create a standard marker panel for any organoid type?
There is no universal panel that establishes fidelity for every organoid. We build a focused panel around the model, biological expectation, comparison, and intended conclusion. Literature-supported markers still require compatibility review for the submitted preparation and assay conditions.
Can staining prove that an organoid is fully equivalent to its source tissue?
No. Histology and immunostaining evaluate selected structural and protein-level features in the tested material. They do not establish global genetic, transcriptomic, epigenetic, functional, or cell-composition equivalence.
Can you quantify IHC or IF images?
Yes, when image quality and study design support a defensible metric. The biological unit, field-selection rule, segmentation approach, threshold, background handling, and exclusions must be defined so the number can be traced back to the underlying image.
What causes high background or weak signal in organoid IF?
Possible contributors include fixation, antigen masking, antibody compatibility, insufficient blocking, autofluorescence, residual matrix, incomplete permeabilization, limited antibody penetration, washing, mounting, and acquisition settings. Controls and a focused pilot help distinguish these technical factors from biology.
Can you compare different passages, batches, or treatments?
Yes, when groups are defined before processing and the biological units are appropriate. Passage, batch, condition, collection time, preparation route, and acquisition settings should be balanced or documented so they are not mistaken for the primary biological effect.
What information should I provide for a feasibility review?
Provide the organoid type and source, culture matrix, passage and batch, research question, comparison groups, available material, preservation state, target markers, antibody information, desired imaging or quantification, controls, and any downstream sequencing plan.
Case Study: H&E, IHC, and IF Resolve Complementary Features in Lung Cancer Assembloids
Source. Zhang and colleagues reported an independent 2024 study in Nature Communications describing a patient-specific lung cancer assembloid research model. The work did not involve CD Genomics and is presented here only as a published example of how complementary imaging evidence can be organized.
Research question. The investigators asked whether assembloids generated from lung cancer organoids and tumor-microenvironment cells retained selected histological and cellular features of the source tumors. The comparison required more than one image type because architecture, epithelial markers, stromal components, and immune-cell localization are not measured by a single stain.
Methods. Figure 3 combined H&E images of assembloids and corresponding source tumors with marker-based images. The study examined CK7 and EpCAM expression and used IF to localize alpha-SMA with EpCAM and CD3 with EpCAM in tumor fragments and matched assembloids. The published methods describe fixation, blocking and permeabilization, antibody incubation, fluorescent secondary antibodies, nuclear counterstaining, confocal imaging, and image review.
Results. Within the study's models and tested samples, H&E supported comparison of selected histological features, while IHC and IF showed the distribution of predefined epithelial, stromal, and immune-associated markers. The different image panels contributed complementary evidence rather than a single universal fidelity measurement.
Conclusion. The case illustrates the value of planning H&E, IHC, and IF around one comparison map. It also shows the boundary of the evidence: the images support conclusions about the tested structures and markers under the reported conditions, not complete equivalence of every biological feature and not performance in another organoid system.
References:
- Dekkers JF, Alieva M, Wellens LM, et al. High-resolution 3D imaging of fixed and cleared organoids. Nature Protocols. 2019;14(6):1756-1771.
- Beşikcioğlu HE, Yurteri Ü, Ye L, et al. Protocol for whole-mount immunofluorescence staining of ECM gel-embedded innervated pancreatic organoids. STAR Protocols. 2024;5(2):103132.
- Martinez-Ordoñez A, Cid-Diaz T, Duran A, Han Q, Moscat J, Diaz-Meco MT. Whole-mount staining of mouse colorectal cancer organoids and fibroblast-organoid co-cultures. STAR Protocols. 2023;4(2):102243.
- Kim D, Lim H, Youn J, Park T-E, Kim DS. Scalable production of uniform and mature organoids in a 3D geometrically-engineered permeable membrane. Nature Communications. 2024;15:9420.
- Bouchard G, Zhang W, Ilerten I, et al. A quantitative spatial cell-cell colocalizations framework enabling comparisons between in vitro assembloids and pathological specimens. Nature Communications. 2025;16:1392.
- Zhang Y, Hu Q, Pei Y, et al. A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments. Nature Communications. 2024;15:3382.